Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017
Updated MT-3724 Clinical Results Expected in 1H18
At Least Two New MTEM Products to Enter the Clinic in 2018
AUSTIN, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today provided a review of 2017 company progress as well as an update on expected 2018 milestones.
“2017 was a transformational year for Molecular Templates as we became a publicly traded company, raised $60 million from institutional investors and our partner Takeda Pharmaceuticals, made important clinical progress with our lead pipeline program MT-3724, and expanded and advanced our collaboration with Takeda,” said Eric Poma Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “We expect multiple value enhancing events throughout 2018, with our team focused on generating more data for our lead product candidate MT-3724, advancing additional products into the clinic, making continued progress with our partner Takeda, and exploring additional business development opportunities.”
Corporate Updates
Summary of Key 2017 Accomplishments
Expected 2018 Milestones
MT-3724 (targeting CD20)
MT-4019 (targeting CD38)
Pipeline
Business development
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this press release regarding Molecular Templates’ strategy, future operations and plans are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the development, potential benefits and uses of and markets for Molecular Templates’ product candidates, including MT-3724, MT-4019 and evofosfamide, and anticipated clinical trials, including timing and potential results. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Molecular Templates makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of MT-3724, MT-4019 and evofosfamide and other risks described in the “Risk Factors” section of Molecular Templates’ most recent 10-K, 10-Q, and other reports on file with the SEC. Molecular Templates does not assume any obligation to update any forward-looking statements, except as required by law.
Investor Contact:
Andrew McDonald, Ph.D.
[email protected]
646-597-6987
Adam Cutler
Chief Financial Officer
[email protected]
862-304-4006
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member